Top View
- (12) United States Patent (10) Patent No.: US 8.426,475 B2 Weidner Et Al
- 2021 Equine Prohibited Substances List
- Global Strategy for Asthma Management and Prevention Online Appendix
- Section B Changed Classes/Guidelines Final Version Date of Issue
- Supplementary File
- Benefit Assessment of Medicinal Products with New Active
- Inhalation Composition Containing Aclidinium for Treatment of Asthma and Chronic Obstructive Pulmonary Disease
- Amineptine, Amiphenazole, Amphetamines, Bromantan, Caffeine
- Statistical Analysis Plan
- Chemical Structure-Related Drug-Like Criteria of Global Approved Drugs
- Shelley 2004 Cardiovasc B2ag
- Study Protocols
- TUE Physician Guidelines ASTHMA 1. Medical Condition
- Justification
- (12) United States Patent (Io) Patent No.: US 9,526,824 B2 Ferrari Et Al
- Inhalation Composition Containing Aclidinium for Treatment of Asthma and Chronic Obstructive Pulmonary Disease
- NVA237 / Glycopyrronium Bromide Multinational, Multi-Database Cohort
- Customs Tariff - Schedule Xxi - 1
- PASS Information
- Formoterol As Reliever Medication in Asthma: a Post-Hoc Analysis of The
- Examples of Prohibited Substances & Methods
- 2020 GINA Appendix
- Literature Search Strategy for Treatment of Stable
- Screening of B-2 Agonists and Confirmation of Fenoterol
- 2017 Summary of Major Modifications and Explanatory Notes
- Long-Acting Beta2-Agonists for Chronic Asthma in Adults and Children Where Background Therapy Contains Varied Or No Inhaled Corticosteroid (Review)
- The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
- Supplementary Materials
- Non-Interventional Study Protocol
- The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
- Chirality of Β2-Agonists. an Overview of Pharmacological Activity, Stereoselective Analysis, and Synthesis
- QVA149 / Indacaterol / Glycopyrronium Bromide
- Harmonized Tariff Schedule of the United States (2003) -- Supplement 1 Annotated for Statistical Reporting Purposes
- European Patent Office © Publication Number: 0 471 468 A1 Office Europeen Des Brevets
- PASS Information
- Asthma and Doping in Sports
- Substance Activity
- Beta2-Adrenergic Receptor Agonists: a Comparison of Reproterol, Fenoterol and Salbutamol on Monocyte Cyclic-Amp and Leukotriene B4 Production in Vitro
- Short-Acting Beta Agonists and Risk of Myocardial Ischaemia Final SPC
- Pirbuterol/Salbutamol 1131